3,878 Shares in Natera, Inc. $NTRA Acquired by Allworth Financial LP

Key Points

• Allworth Financial acquired 3,878 Natera shares valued at approximately $1.05 million during the second quarter. Institutional investors and hedge funds collectively own 99.90% of Natera’s stock.
• Natera insiders sold 181,045 shares worth approximately $41.3 million over the last quarter, including sales by CEO Steven Leonard Chapman and Director Gail Boxer Marcus.
• Analysts maintain a generally positive outlook, with Natera carrying a “Moderate Buy” consensus rating and a $319.38 average price target. The company’s latest quarterly revenue rose 37.7% year over year to $752.75 million, while its loss per share was narrower than expected.

Allworth Financial LP purchased a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 3,878 shares of the medical research company's stock, valued at approximately $1,053,000.

A number of other large investors have also made changes to their positions in NTRA. JPMorgan Chase & Co. raised its position in shares of Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company's stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Natera during the second quarter worth $2,962,770,000. Wellington Management Group LLP grew its holdings in shares of Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company's stock valued at $1,140,026,000 after buying an additional 2,420,263 shares during the last quarter. State Street Corp increased its position in shares of Natera by 2.2% in the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company's stock valued at $545,624,000 after acquiring an additional 72,087 shares during the period. Finally, Coatue Management LLC increased its position in shares of Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company's stock valued at $603,270,000 after acquiring an additional 2,463,008 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Natera

In other Natera news, Director Gail Boxer Marcus sold 11,000 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the transaction, the director owned 6,183 shares in the company, valued at approximately $1,343,009.43. This represents a 64.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 41,124 shares of the firm's stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the sale, the chief executive officer directly owned 108,743 shares in the company, valued at approximately $24,035,465.29. The trade was a 27.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 181,045 shares of company stock worth $41,330,968 over the last quarter. Company insiders own 5.05% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on NTRA. Morgan Stanley reissued an "overweight" rating and issued a $355.00 price objective on shares of Natera in a report on Monday, August 10th. Robert W. Baird set a $348.00 target price on Natera in a report on Friday, August 7th. Zacks Research upgraded Natera from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 12th. Stephens increased their price target on shares of Natera from $305.00 to $350.00 and gave the stock an "overweight" rating in a report on Wednesday, August 12th. Finally, Wall Street Zen lowered shares of Natera from a "buy" rating to a "hold" rating in a research report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Natera presently has an average rating of "Moderate Buy" and a consensus price target of $319.38.

Natera Price Performance

NTRA opened at $332.03 on Friday. The firm has a fifty day moving average price of $274.24 and a 200 day moving average price of $229.39. Natera, Inc. has a 1 year low of $157.43 and a 1 year high of $333.56. The stock has a market cap of $47.86 billion, a P/E ratio of -244.14 and a beta of 1.51.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm's revenue was up 37.7% on a year-over-year basis. During the same quarter last year, the business earned ($0.74) earnings per share. Equities analysts expect that Natera, Inc. will post -1.02 EPS for the current year.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source